Jan 20, 2026 11:52AM H.C. Wainwright Downgrades Rapt Therapeutics (RAPT) to Neutral

Jan 20, 2026 09:29AM Guggenheim Downgrades Rapt Therapeutics (RAPT) to Neutral

Jan 20, 2026 08:03AM Piper Sandler Downgrades Rapt Therapeutics (RAPT) to Neutral

Jan 20, 2026 07:08AM Clear Street Downgrades Rapt Therapeutics (RAPT) to Hold

Jan 20, 2026 06:58AM GSK to acquire RAPT Therapeutics for $2.2 billion in food allergy deal

Jan 9, 2026 04:51AM Piper Sandler Starts Rapt Therapeutics (RAPT) at Overweight

Dec 18, 2025 05:30AM TD Cowen Starts Rapt Therapeutics (RAPT) at Buy

Oct 28, 2025 06:42AM Rapt Therapeutics (RAPT) PT Raised to $72 at H.C. Wainwright

Oct 27, 2025 06:08AM Guggenheim Starts Rapt Therapeutics (RAPT) at Buy, PT $70

Oct 21, 2025 05:32AM Rapt Therapeutics (RAPT) PT Raised to $48 at Wells Fargo

Oct 20, 2025 12:30PM JPMorgan Upgrades Rapt Therapeutics (RAPT) to Overweight

Oct 20, 2025 09:23AM Barclays on Rapt Therapeutics (RAPT): 'RPT904 shows numerically better UAS7 improvements compared to Xolair at every time point'

Oct 13, 2025 05:31AM Barclays Starts Rapt Therapeutics (RAPT) at Overweight

Sep 29, 2025 04:38PM Rapt Therapeutics (RAPT) PT Raised to $41 at Clear Street

Sep 29, 2025 05:45AM RAPT Therapeutics (RAPT) Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

Sep 26, 2025 06:17AM Leerink Partners Upgrades Rapt Therapeutics (RAPT) to Outperform

Aug 8, 2025 06:28AM Rapt Therapeutics (RAPT) PT Lowered to $38 at Wells Fargo

Aug 7, 2025 09:38AM RAPT Therapeutics, Inc. (RAPT) Misses Q2 EPS by 56c

Aug 7, 2025 05:22AM Rapt Therapeutics (RAPT) PT Raised to $24 at Clear Street

Jul 30, 2025 02:28AM JPMorgan Upgrades Rapt Therapeutics (RAPT) to Neutral

Jul 10, 2025 06:42AM Rapt Therapeutics (RAPT) PT Raised to $27 at H.C. Wainwright

Jun 23, 2025 08:04AM RAPT Therapeutics (RAPT) Appoints Scott Braunstein and Ashley Dombkowski to its Board

Jun 13, 2025 09:00AM RAPT Therapeutics (RAPT) Sets June 16 as Effective Date of 1:8 Reverse Share Split

Jun 5, 2025 04:52PM Clear Street Starts Rapt Therapeutics (RAPT) at Buy

May 22, 2025 06:57AM H.C. Wainwright Assumes Rapt Therapeutics (RAPT) at Buy

May 22, 2025 05:48AM Rapt Therapeutics (RAPT) PT Lowered to $1 at UBS

Mar 10, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Rapt Therapeutics (RAPT)

Jan 6, 2025 04:38PM RAPT Therapeutics (RAPT) Announces Resignation of William Rieflin from Board

Dec 26, 2024 06:33AM H.C. Wainwright Upgrades Rapt Therapeutics (RAPT) to Buy

Dec 23, 2024 07:12AM RAPT Therapeutics (RAPT) Announces $150M Private Placement

Dec 23, 2024 07:01AM RAPT Therapeutics (RAPT) and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

Nov 25, 2024 06:52AM H.C. Wainwright Reiterates Neutral Rating on Rapt Therapeutics (RAPT)

Nov 12, 2024 04:54PM RAPT Therapeutics, Inc. (RAPT) Tops Q3 EPS by 9c

Nov 12, 2024 04:08PM Leerink Partners Reiterates Market Perform Rating on Rapt Therapeutics (RAPT)

Nov 12, 2024 04:04PM Stifel Downgrades Rapt Therapeutics (RAPT) to Hold

Nov 11, 2024 11:45AM JPMorgan Downgrades Rapt Therapeutics (RAPT) to Underweight

Nov 11, 2024 08:04AM RAPT Therapeutics (RAPT): Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

Aug 20, 2024 06:43AM H.C. Wainwright Reiterates Neutral Rating on Rapt Therapeutics (RAPT)

Aug 8, 2024 09:23AM RAPT Therapeutics, Inc. (RAPT) Tops Q2 EPS by 1c